Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63/MVA ME-TRAP malaria vaccine study in Burkinabe infants and children
PACTR201208000404131Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Nov 2012
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ChAd63 ME-TRAP, MVA ME-TRAP and Rabies vaccine in malaria (2 arms), sponsored by University of Oxford. Primary endpoint: Protective efficacy against clinical malaria. Started Nov 2012; status: completed.
02
Drugs
ChAd63 ME-TRAPMVA ME-TRAPRabies vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201208000404131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201208000404131.